HBI 0201-ESO TCRT / Hadassah Medical Organization - LARVOL DELTA

Successful transfer and prolonged persistence of engineered lymphocytes with T-cell receptor targeting NY-ESO-1 (ESMO-TAT 2023) - P1/2 | "Clinical trial identification HBI-0201-ESO TCRT- NCT05296564...Patients underwent lympho-depletion (Cyclophosphamide 250mg/m 2 and Fludarabine 25mg/m 2 D1-3) and 5 days later received 1*10 9 engineered TCRs, followed by 3-days of continues IL-2 (18x10 6 IU/24H)...Conclusions This is an initial dose of a first-in-human investigator-initiated trial, using a specificity-enhanced third generation TCR targeting NY-ESO-1. A durable persistence was shown for the modified lymphocytes associated with short-term stabilization of metastatic disease and with acceptable safety."

Breast Cancer • Choroidal Melanomas • Melanoma • Ocular Melanoma • Oncology • Sarcoma • Solid Tumor • Synovial Sarcoma • Triple Negative Breast Cancer • CTAG1B • HLA-A • IL2

Anti-NY-ESO-1 TCR-Gene Engineered Lymphocytes Given by Infusion to Patients With NY-ESO-1 -Expressing Metastatic Cancers (clinicaltrials.gov) - P1/2 | N=3 | Recruiting | Sponsor: Hadassah Medical Organization

New P1/2 trial • Bladder Cancer • Breast Cancer • Lung Cancer • Melanoma • Neuroblastoma • Non Small Cell Lung Cancer • Oncology • Ovarian Cancer • Sarcoma • Soft Tissue Sarcoma • Solid Tumor • Synovial Sarcoma • Triple Negative Breast Cancer • Urothelial Cancer